Molecular docking and pharmacophore filtering in the Discovery of dual-inhibitors for human leukotriene A4 hydrolase and leukotriene C4 synthase

Journal of Chemical Information and Modeling

Volumn 51, Issue 1, 2011, Pages 33-44

  Thangapandian, Sundarapandian ^a   John, Shalini ^a   Sakkiah, Sugunadevi ^a   Lee, Keun Woo ^a  

^a Gyeongsang National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROLASES; MOLECULAR MODELING;

ARACHIDONIC ACIDS; CHEMICAL ENTITY; CHEMICAL FEATURES; COMMON FEATURES; DUAL INHIBITORS; MOLECULAR DOCKING; MULTIPLE TARGETS; PHARMACOPHORE MODELS;

PHARMACODYNAMICS;

ENZYME INHIBITOR; EPOXIDE HYDROLASE; GLUTATHIONE TRANSFERASE; LEUKOTRIENE A4; LEUKOTRIENE A4 HYDROLASE; LEUKOTRIENE C4 SYNTHASE; LEUKOTRIENE-C4 SYNTHASE;

ARTICLE; BINDING COMPETITION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG DEVELOPMENT; ENZYME ACTIVE SITE; FACTUAL DATABASE; HUMAN; METABOLISM; METHODOLOGY; REPRODUCIBILITY;

BINDING, COMPETITIVE; CATALYTIC DOMAIN; DATABASES, FACTUAL; DRUG DISCOVERY; ENZYME INHIBITORS; EPOXIDE HYDROLASES; GLUTATHIONE TRANSFERASE; HUMANS; LEUKOTRIENE A4; MODELS, MOLECULAR; REPRODUCIBILITY OF RESULTS;

EID: 79952587858     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci1002813     Document Type: Article

References (37)

1. Nigus, D.; Workalemahu, M. On the paradigm shift towards multitarget selective drug design. Curr. Comput. Aided Drug Des. 2008, 4, 76-90.
2. Wei, D.; Jiang, X.; Zhou, L.; Chen, J.; Chen, Z.; He, C.; Yang, K.; Liu, Y.; Pei, J.; Lai, L. Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. J. Med. Chem. 2008, 51, 7882-7888.
3. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands. Drug Discovery Today 2004, 9, 641-651. (Pubitemid 38981718)
4. Grant, R. Z.; Joseph, L.; Curtis, T. K. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discovery Today 2007, 12, 34-42.
5. Csermely, P.; Agoston, V.; Pongor, S. The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol. Sci. 2005, 26, 178-182. (Pubitemid 40432652)
6. Huang, S. Rational drug discovery: what can we learn from regulatory networks. Drug Discovery Today 2002, 7, S163-S169.
7. Borisy, A. A.; Elliott, P. J.; Hurst, N. W.; Lee, M. S.; Lehar, J.; Price, E. R.; Serbedzija, G.; Zimmermann, G. R.; Foley, M. A.; Stockwell, B. R.; Keith, C. T. Systematic discovery of multicomponent therapeutics. Proc. Natl. Acad. Sci. 2003, 100, 7977-7982. (Pubitemid 36760080)
8. Morphy, R.; Rankovic, Z. Fragments, network biology and designing multiple ligands. Drug Discovery Today 2007, 12, 156-160. (Pubitemid 46176667)
9. Morphy, R. The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds. J. Med. Chem. 2006, 49, 2969-2978.
10. Xiao, H. M.; Zhe, S.; Chunyan, T.; Yuyang, J.; Mei, L. G.; Boon, C. L.; Yu, Z. C. In-silico approaches to multi-target drug discovery computer aided multi-target drug design, multi-target virtual screening. Pharm. Res. 2010, 27, 739-749.
11. Sheng, Y. H.; Xiaoqin, Z. Efficient molecular docking of NMR structures: Application to HIV-1 protease. Protein Sci. 2007, 16, 43-51.
12. Thunnissen, M. M. G. M.; Nordlund, P.; Haeggström, J. Z. Crystal structure of human leukotriene A4 hydrolase, a bifunctional enzyme in inflammation. Nat. Struct. Biol. 2001, 8, 131-135. (Pubitemid 32117699)
13. Samuelsson, B.; Dahlen, S. E.; Lindgren, J. A.; Rouzer, C. A.; Serhan, C. N. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987, 237, 1171-1176. (Pubitemid 17131222)
14. Steele, V. E.; Holmes, C. A.; Hawk, E. T.; Kopelovich, L.; Lubet, R. A.; Crowell, J. A.; Sigman, C. C.; Kelloff, G. J. Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol., Biomarkers Prev. 1999, 8, 467-483. (Pubitemid 29230553)
15. Molina, D. M.; Wetterholm, A.; Kohl, A.; McCarthy, A. A.; Niegowski, D.; Ohlson, E.; Hammarberg, T.; Eshaghi, S.; Haeggstrom, J. Z.; Nordlund, P. Structural basis for synthesis of inflammatory mediators by human leukotriene C4 synthase. Nature 2007, 448, 613-617.
16. Rao, N. L.; Dunford, P. J.; Xue, X.; Jiang, X.; Lundeen, K. A.; Coles, F.; Riley, J. P.; Williams, K. N.; Grice, C. A.; Edwards, J. P.; Karlsson, L.; Fourie, A. M. Anti-inflammatory activity of a potent, selective leukotriene A4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor Zileuton. J. Pharmacol. Exp. Ther. 2007, 321, 1154-1160. (Pubitemid 46762702)
17. Henderson, W. R. The role of leukotrienes in inflammation. Ann. Intern. Med. 1994, 121, 684-697.
18. Yoshimoto, T.; Soberman, R. J.; Spur, B.; Austen, K. F. Properties of highly purified leukotriene C4 synthase of guinea pig lung. J. Clin. Invest. 1988, 81, 866-871. (Pubitemid 18079738)
19. Maybridge; Maybridge Chemical Co., Cornwall, U. K.; www.maybridge.com, accessed July 20, 2010.
20. Sandanayaka, V.; Mamat, B.; Mishra, R. K.; Winger, J.; Krohn, M.; Zhou, L. M.; Keyvan, M.; Enache, L.; Sullins, D.; Onua, E.; Zhang, J.; Halldorsdottir, G.; Sigthorsdottir, H.; Thorlaksdottir, A.; Sigthorsson, G.; Thorsteinnsdottir, M.; Davies, D. R.; Stewart, L. J.; Zembower, D. E.; Andresson, T.; Kiselyov, A. S.; Singh, J.; Gurney, M. E. Discovery of 4-[(2S)-2-{[4-(4-Chlorophenoxy) phenoxy]methyl}-1-pyrrolidinyl]butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis. J. Med. Chem. 2010, 53, 573-585.
21. Davies, D. R.; Mamat, B.; Magnusson, O. T.; Christensen, J.; Haraldsson, M. H.; Mishra, R.; Pease, B.; Hansen, E.; Singh, J.; Zembower, D.; Kim, H.; Kiselyov, A. S.; Burgin, A. B.; Gurney, M. E.; Stewart, L. J. Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography. J. Med. Chem. 2009, 52, 4694-4715.
22. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations. J. Comput. Chem. 1983, 4, 187-217.
23. Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Taylor, R. D. Improved protein-ligand docking using GOLD. Proteins 2003, 52, 609-623. (Pubitemid 37034158)
24. Cheng, F.; Wang, Q.; Chen, M.; Quiocho, F. A.; Ma, J. Molecular docking study of the interactions between the thioesterase domain of human fatty acid synthase and its ligands. Proteins 2008, 70, 1228-1234. (Pubitemid 351304083)
25. Khim, S. K.; Bauman, J.; Evans, J.; Freeman, B.; King, B.; Kirkland, T.; Kochanny, M.; Lentz, D.; Liang, A.; Mendoza, L.; Phillips, G.; Tseng, J. L.; Wei, R. G.; Ye, H.; Yu, L.; Parkinson, J.; Guilford, W. J. Discovery of novel and potent aryl diamines as leukotriene A4 hydrolase inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 3895-3898.
26. Penning, T. D.; Chandrakumar, N. S.; Desai, B. N.; Djuric, S. W.; Gasiecki, A. F.; Malecha, J. W.; Miyashiro, J. M.; Russell, M. A.; Askonas, L. J.; Gierse, J. K.; Harding, E. I.; Highkin, M. K.; Kachur, J. F.; Kim, S. H.; Villani-Price, D.; Pyla, E. Y.; Ghoreishi-Haack, N. S.; Smith, W. G. Synthesis of imidazopyridines and purines as potent inhibitors of leukotriene A4 hydrolase. Bioorg. Med. Chem. Lett. 2003, 13, 1137-1139. (Pubitemid 36331817)
27. Penning, T. D.; Russell, M. A.; Chen, B. B.; Chen, H. Y.; Liang, C. D.; Mahoney, M. W.; Malecha, J. W.; Miyashiro, J. M.; Yu, S. S.; Askonas, L. J.; Gierse, J. K.; Harding, E. I.; Highkin, M. K.; Kachur, J. F.; Kim, S. H.; Villani-Price, D.; Pyla, E. Y.; Ghoreishi-Haack, N. S.; Smith, W. G. Synthesis of potent leukotriene A4 hydrolase inhibitors. Identification of 3-[methyl[3-[4-(phenylmethyl) phenoxy] propyl]amino]propanoic acid. J. Med. Chem. 2002, 45, 3482-3490. (Pubitemid 34824036)
28. Sala, A.; Folco, G.; Henson, P. M.; Murphy, R. C. Pharmacological modulation of human platelet leukotriene C4-synthase. Biochem. Pharmacol. 1997, 53, 905-908. (Pubitemid 27145793)
29. Hutchinson, J. H.; Charleson, S.; Evans, J. F.; Falgueyret, J. P.; Hoogsteen, K.; Jones, T. R.; Kargman, S.; Macdonald, D.; McFarlane, C. S.; Nicholson, D. W.; Piechuta, H.; Riendeau, D.; Scheigetz, J.; Therien, M.; Girard, Y. Thiopyranol[2, 3, 4-c, d]indoles as inhibitors of 5-lipoxygenase, 5-lipoxygenase-activating protein, and leukotriene C4 synthase. J. Med. Chem. 1995, 38, 4538-4547.
30. Tiwari, R.; Mahasenan, K.; Pavlovicz, R.; Li, C.; Tjarks, W. Carborane clusters in computational drug design: a comparative docking evaluation using Autodock, Flexx, Glide, and Surflex. J. Chem. Inf. Model. 2009, 49, 1581-1589.
31. Kansal, N.; Silakari, O.; Ravikumar, M. Three dimensional pharmacophore modelling for c-Kit receptor tyrosine kinase inhibitors. Eur. J. Med. Chem. 2010, 45, 393-404.
32. Ekins, S.; De Groot, M. J.; Jones, J. P. Pharmacophore and threedimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites. Drug Metab. Dispos. 2001, 29, 936-944. (Pubitemid 32605906)
33. Charlier, C.; Henichart, J. P.; Durant, F.; Wouters, J. Structural insights into human 5-lipoxygenase inhibition: combined ligand-based and target-based approach. J. Med. Chem. 2006, 49, 186-195. (Pubitemid 43077332)
34. Thangapandian, S.; John, S.; Sakkiah, S.; Lee, K. W. Ligand and structure based pharmacophore modeling to facilitate novel histone deacetylase 8 inhibitor design. Eur. J. Med. Chem. 2010, 45, 4409-4417.
35. John, S.; Thangapandian, S.; Sakkiah, S.; Lee, K. W. Identification of potent virtual leads to design novel indoleamine 2, 3-dioxygenase inhibitors: pharmacophore modeling and molecular docking studies. Eur. J. Med. Chem. 2010, 45, 4004-4012.
36. Laskowski, R. A.; Hutchinson, E. G.; Michie, A. D.; Wallace, A. C.; Jones, M. L.; Thornton, J. M. PDBsum: a web-based database of summaries and analyses of all PDB structures. Trends Biochem. Sci. 1997, 22, 488-490. (Pubitemid 27515917)
37. Laskowski, R. A. PDBsum new things. Nucleic Acids. Res. 2009, 37, D355-D359.